Literature DB >> 26971415

Assessment of PI-RADS v2 for the Detection of Prostate Cancer.

Moritz Kasel-Seibert1, Thomas Lehmann2, René Aschenbach3, Felix V Guettler3, Mohamed Abubrig4, Marc-Oliver Grimm5, Ulf Teichgraeber3, Tobias Franiel3.   

Abstract

PURPOSE: To evaluate the diagnostic performance and inter-reader reliability of the multiparametric magnetic resonance imaging (mpMRI) based prostate imaging reporting and data system (PI-RADS) version 1 and version 2 for the assessment of prostate cancer.
MATERIAL AND METHODS: A cohort of 82 patients underwent endorectal mpMRI at 1.5T. Patients had at least one lesion with a PI-RADS v1 assessment category of ≥3 and were selected for targeted in-bore MR-guided biopsy in a subsequent session. The results of the histopathological workup were used as reference standard. All lesions were retrospectively evaluated according to PI-RADS v2 by an experienced and unexperienced blinded reader. Diagnostic performance was compared by analyzing the area under the Receiver Operating Characteristics Curve (AUC). The weighted kappa method was used to calculate inter-reader reliability.
RESULTS: Targeted MR-guided biopsy was performed in 136 lesions and revealed 39 malignant lesions in 31 patients. AUC values increased for the experienced reader (PI-RADS v1 0.79; PI-RADS v2 0.83) and unexperienced reader (PI-RADS v1 0.70; PI-RADS v2 0.83). When excluding the cases of low grade cancer (Gleason score=3+3), AUC values increased further for the experienced reader (PI-RADS v1 0.88; PI-RADS v2 0.91) and unexperienced reader (PI-RADS v1 0.78; PI-RADS v2 0.90). Specificity at the selected threshold of a PI-RADS v1/v2 assessment category ≥4 improved for both readers. Inter-reader agreement increased from κ=0.55 in PI-RADS v1 to κ=0.68 in v2.
CONCLUSION: PI-RADS v2 improved diagnostic performance for the assessment of suspicious intraprostatic lesions identified in PI-RADS v1 for both readers and led to higher inter-reader reliability. These results suggest that PI-RADS v2 is a reliable and replicable reporting system for the assessment of prostate cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biopsy; ESUR; MRI; Prostate cancer

Mesh:

Year:  2016        PMID: 26971415     DOI: 10.1016/j.ejrad.2016.01.011

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  53 in total

1.  Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study.

Authors:  Matthew D Greer; Anna M Brown; Joanna H Shih; Ronald M Summers; Jamie Marko; Yan Mee Law; Sandeep Sankineni; Arvin K George; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2016-07-08       Impact factor: 4.813

2.  Classification of Clinical Significance of MRI Prostate Findings Using 3D Convolutional Neural Networks.

Authors:  Alireza Mehrtash; Alireza Sedghi; Mohsen Ghafoorian; Mehdi Taghipour; Clare M Tempany; William M Wells; Tina Kapur; Parvin Mousavi; Purang Abolmaesumi; Andriy Fedorov
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-03-03

3.  Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?

Authors:  Richard Hoffmann; Callum Logan; Michael O'Callaghan; Kirsten Gormly; Ken Chan; Darren Foreman
Journal:  Int Urol Nephrol       Date:  2017-11-29       Impact factor: 2.370

4.  Classification of suspicious lesions on prostate multiparametric MRI using machine learning.

Authors:  Deukwoo Kwon; Isildinha M Reis; Adrian L Breto; Yohann Tschudi; Nicole Gautney; Olmo Zavala-Romero; Christopher Lopez; John C Ford; Sanoj Punnen; Alan Pollack; Radka Stoyanova
Journal:  J Med Imaging (Bellingham)       Date:  2018-09-06

Review 5.  [MRI of the prostate].

Authors:  D Nörenberg; O Solyanik; B Schlenker; G Magistro; B Ertl-Wagner; D A Clevert; C Stief; M F Reiser; M D'Anastasi
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 6.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 7.  A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.

Authors:  Li Zhang; Min Tang; Sipan Chen; Xiaoyan Lei; Xiaoling Zhang; Yi Huan
Journal:  Eur Radiol       Date:  2017-06-27       Impact factor: 5.315

8.  The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.

Authors:  Ximing Wang; Jie Bao; Xiaoxia Ping; Chunhong Hu; Jianquan Hou; Fenglin Dong; Lingchuan Guo
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

9.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.

Authors:  Liran Domachevsky; Natalia Goldberg; Hanna Bernstine; Meital Nidam; David Groshar
Journal:  Eur Radiol       Date:  2018-05-30       Impact factor: 5.315

Review 10.  Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.

Authors:  Elmira Hassanzadeh; Daniel I Glazer; Ruth M Dunne; Fiona M Fennessy; Mukesh G Harisinghani; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.